Novo Nordisk | NVO - Cost Of Sales


Novo Nordisk reported DKK2.66B in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
ANI Pharmaceuticals USD 114.5M 8.38M Mar/2026
Aurora Cannabis CAD 8.22M 80.38M Mar/2026
Bausch Health Companies USD 997M 18M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Canopy Growth CAD 62.98M 9.91M Mar/2026
Corcept Therapeutics USD 4.06M 1.18M Jun/2026
Drreddys Laboratories INR 32.13B 8.34B Mar/2026
Eli Lilly USD 3.27B 309M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Merck USD 3.14B 200M Jun/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novartis USD 3.71B 251M Jun/2026
Novo Nordisk DKK 17.1B 3.5B Jun/2026
Novo Nordisk DKK 2.66B 10.94B Jun/2026
Pacira USD 58.49M 7.75M Jun/2026
Perrigo USD 708.9M 65.2M Jun/2026
Phibro Animal Health USD 240.42M 2.58M Dec/2025
Prestige Brands USD 140.76M 9.53M Mar/2026
Sanofi EUR 3.02B 656M Jun/2026
Supernus Pharmaceuticals USD 59M 9.97M Jun/2026
Zoetis USD 672M 71M Mar/2026